Combination immunotherapy for advanced liver cancer with hepatitis B
Treatments studied
Part of Cancer, Infections clinical trials.
This trial tests a new combination of three drugs (BRII-5395, sintilimab, and bevacizumab) for advanced hepatocellular carcinoma (liver cancer) in patients with hepatitis B who have not responded well to previous treatments. The goal is to evaluate whether this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Advanced or metastatic liver cancer (stages B or C) that cannot be surgically removed or treated with transplant
- Must have already tried at least one previous immunotherapy treatment that did not work
- Adequate blood cell counts and organ function (kidney, liver, heart)
- Expected to live more than 3 months
- Active hepatitis B infection (HBsAg positive at screening)
- No major unresolved side effects from previous cancer treatments (grade 2 or higher)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
This trial tests a combination of local treatments (like TACE or HAIC) with bevacizumab and an immunotherapy drug (PD-1/L1 inhibitor) for advanced liver cancer. It may be an option if you haven't had systemic therapy before or if your previous treatment stopped working.
This trial tests a combination of immunotherapy (checkpoint inhibitors) and anti-VEGF therapy (which blocks blood vessel growth to tumors) with or without local treatments (like chemoembolization) for advanced liver cancer. It aims to see if the combination works better than current treatments.
This study looks at different first-line immunotherapy treatments for people with advanced liver cancer that cannot be treated with surgery or local therapies. It aims to understand how well these treatments work and how they affect the body's immune system.
This trial tests whether adding a combination of three drugs (anti-CTLA-4, anti-PD-1, and bevacizumab) before and after surgery can help people with resectable liver cancer. The goal is to see if this approach improves outcomes compared to standard treatment.
This trial tests a new combination of two immunotherapy drugs (IBI310 and sintilimab) as a first treatment for advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and works better than current options.
Hear when a new Advanced HBV-Related Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.